Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.

Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2013;33(3):807-22. doi: 10.3233/JAD-2012-110029.

PMID:
23034521
[PubMed - indexed for MEDLINE]
2.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
[PubMed - indexed for MEDLINE]
3.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.

Curr Clin Pharmacol. 2008 May;3(2):123-31. Review.

PMID:
18700307
[PubMed - indexed for MEDLINE]
4.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.

Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM.

Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21. Review.

PMID:
23519967
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Fluid biomarkers in Alzheimer's disease - current concepts.

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Review.

PMID:
23800368
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1. Review.

PMID:
23642576
[PubMed - indexed for MEDLINE]
7.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008. Review.

PMID:
20451871
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Papaliagkas VT.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. Review.

PMID:
23489287
[PubMed - indexed for MEDLINE]
9.

Frailty among Alzheimer's disease patients.

Koch G, Belli L, Giudice TL, Lorenzo FD, Sancesario GM, Sorge R, Bernardini S, Martorana A.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):507-11. Review.

PMID:
23574166
[PubMed - indexed for MEDLINE]
10.

Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.

Parnetti L, Chiasserini D.

Biomark Med. 2011 Aug;5(4):479-84. doi: 10.2217/bmm.11.48. Review.

PMID:
21861669
[PubMed - indexed for MEDLINE]
11.

CSF markers for incipient Alzheimer's disease.

Blennow K, Hampel H.

Lancet Neurol. 2003 Oct;2(10):605-13. Review.

PMID:
14505582
[PubMed - indexed for MEDLINE]
12.

Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease.

Rosén C, Zetterberg H.

Curr Opin Psychiatry. 2013 May;26(3):276-82. doi: 10.1097/YCO.0b013e32835f6747. Review.

PMID:
23493130
[PubMed - indexed for MEDLINE]
13.

The diagnostic value of CSF amyloid-β(43) in differentiation of dementia syndromes.

Bruggink KA, Kuiperij HB, Claassen JA, Verbeek MM.

Curr Alzheimer Res. 2013 Dec;10(10):1034-40. Review.

PMID:
24156268
[PubMed - indexed for MEDLINE]
14.

Biomarker modeling of Alzheimer's disease.

Jack CR Jr, Holtzman DM.

Neuron. 2013 Dec 18;80(6):1347-58. doi: 10.1016/j.neuron.2013.12.003. Review.

PMID:
24360540
[PubMed - indexed for MEDLINE]
15.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E.

Biomark Med. 2012 Aug;6(4):409-17. doi: 10.2217/bmm.12.39. Review.

PMID:
22917143
[PubMed - indexed for MEDLINE]
16.

Analytical aspects of molecular Alzheimer's disease biomarkers.

Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H.

Biomark Med. 2012 Aug;6(4):377-89. doi: 10.2217/bmm.12.44. Review.

PMID:
22917140
[PubMed - indexed for MEDLINE]
17.

[An overview of biomarkers in Alzheimer's disease].

Rong XF, Wang XL.

Yao Xue Xue Bao. 2012 May;47(5):551-7. Review. Chinese.

PMID:
22811995
[PubMed - indexed for MEDLINE]
18.

CSF in Alzheimer's disease.

Zetterberg H, Lautner R, Skillbäck T, Rosén C, Shahim P, Mattsson N, Blennow K.

Adv Clin Chem. 2014;65:143-72. Review.

PMID:
25233613
[PubMed - indexed for MEDLINE]
19.

The use of proteomics in biomarker discovery in neurodegenerative diseases.

Davidsson P, Sjögren M.

Dis Markers. 2005;21(2):81-92. Review.

PMID:
15920295
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L.

Alzheimers Dement. 2014 Nov;10(6):808-817. doi: 10.1016/j.jalz.2014.03.003. Epub 2014 Aug 20. Review.

PMID:
25150736
[PubMed - as supplied by publisher]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk